



Leading US Men's Health Expert Dr Andrew Sun Joins LTR Pharma to support US\$3.7B Market Entry

18 August 2025

Highlights

- Leading Texas urologist from one of the state's largest men's health clinics joins LTR Pharma's Scientific Advisory Board to support US launch strategy.
- Appointment validates significant unmet need for ROXUS® among patients intolerant to oral PDE5s, supporting faster prescriber adoption.
- Dr Sun's expertise to help position ROXUS® and SPONTAN® for U.S. launch in the US\$3.7 billion¹ market.

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to announce the appointment of Dr Andrew Y. Sun, M.D., a fellowship-trained urologist and nationally recognised expert in male sexual and reproductive medicine, to its Scientific Advisory Board ("SAB"). Based in Texas, Dr Sun brings extensive experience in prescribing PDE5 treatment protocols and will advise on integrating LTR's intranasal therapies ROXUS® and SPONTAN® - into treatment pathways for erectile dysfunction (ED), particularly for patients experiencing side effects with existing oral medications.

Dr Sun is Director of Men's Health at [Urology Partners of North Texas](#), one of the state's largest men's health clinics. He trained at Harvard Medical School, completed a residency at the Cleveland Clinic Glickman Urological and Kidney Institute, and undertook fellowship training in Male Reproductive Medicine and Surgery at UCLA. His clinical experience spans ED, ejaculatory dysfunction, male infertility, hormone management, and Peyronie's disease. Dr Sun is an active contributor to US national clinical guidelines and a frequent speaker at leading urology conferences.

He is an active member of the American Urological Association (AUA), the American Society for Reproductive Medicine (ASRM), and the International Society for Sexual Medicine (ISSM). Dr Sun contributes to clinical guidelines for the [Sexual Medicine Society of North America](#) (SMSNA) and leads national training programs in erectile restoration with Boston Scientific.

As a thought leader in men's sexual health, Dr Sun is a frequent presenter at international scientific meetings and has authored multiple peer-reviewed journal articles. His expertise is widely recognised through regular appearances on prominent podcasts, including BackTable Urology, Bionic Health, and Urology Times' "Pearls & Perspectives", where he shares insights on testosterone therapy, men's health program development, and sexual dysfunction management. He has been interviewed at major conferences, including the American Urological Association annual meeting, reflecting his influential position within the urology community.

Dr Andrew Sun, said:

"A sizeable portion of patients experience problematic side effects from higher-dose PDE5 tablets – back pain, heartburn, joint aches – that affect quality of life and intimacy. ROXUS AND SPONTAN offer the rapid onset men want without the



systemic side effects that often compromise their experience. I'm looking forward to introducing these options in my practice as they become available in the US."

LTR Pharma Executive Chairman, Lee Rodne, said:

"Dr Sun's appointment strengthens our US market entry strategy by adding real-world, clinical insight into how and why oral PDE5 therapies fail patients. His expertise will help position ROXUS and SPONTAN as preferred alternatives, accelerating prescriber adoption ahead of our planned US commercial launch in H1 2026, in a market valued at over US\$3.7 billion."

¹Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas.

LTR's lead products, SPONTAN[®] and ROXUS[®], are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW[®], a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com